v3.26.1
Significant Agreements (Tables)
 6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Supplemental Information Related to the BMS Collaboration Agreement
Supplemental information related to the Research Collaboration and License Agreement, or the BMS Collaboration Agreement, with Juno Therapeutics, Inc., a wholly-owned subsidiary of the Bristol-Myers Squibb Company, or BMS, consisted of the following:
(in thousands)June 30,
2026		December 31,
2025
Deferred revenue — related party$7,934 $7,824 
Deferred revenue, net of current — related party$56,033 $58,127 
Three Months Ended
June 30,		Six Months Ended
June 30,
(in thousands)2026202520262025
Revenue recognized that was included in contract liability at the beginning of the period$1,152 $1,061 $2,008 $2,502 
Revenue recognized from performance obligations fully or partially satisfied in previous periods$3 $5 $3 $3